Proto Labs Inc. 2026年季度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549___________________________ FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March31, 2026or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35435 Proto Labs, Inc. (Exact name of registrant as specified in its charter) 41-1939628(I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 23,794,045shares of Common Stock, par value $0.001 per share, were outstanding at April28, 2026. PART I 1.Financial Statements22.Management's Discussion and Analysis of Financial Condition and Results of Operations163.Quantitative and Qualitative Disclosures about Market Risk234.Controls and Procedures23PART II1.Legal Proceedings241A.Risk Factors242.Unregistered Sales of Equity Securities and Use of Proceeds243.Defaults Upon Senior Securities244.Mine Safety Disclosures245.Other Information246.Exhibits25 Notes to Consolidated Financial Statements Note 1 – Basis of Presentation The unaudited interim Consolidated Financial Statements of Proto Labs, Inc. (Protolabs, the Company, we, us or our) have been prepared inaccordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information andwith the instructions to Form 10-Q and Article 10 of Regulation S-X.In the opinion of management, the accompanying financial statementsreflect all adjustments necessary for a fair presentation of the Company’s statements of financial position, results of operations and cash The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions thataffect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements andduring the reporting period. Actual results could materially differ from these estimates. For further information, refer to the audited The accompanying Consolidated Balance Sheet as of December31, 2025 was derived from the audited Consolidated Financial Statementsbut does not include all disclosures required by U.S. GAAP for a full set of financial statements. This Quarterly Report on Form 10-Q should Note 2 – Recent Accounting Pronouncements The Company did not recently adopt any accounting pronouncements that had a material impact on the Company's Consolidated FinancialStatements. Apart from the items discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, there are no other newaccounting pronouncements that are expected to have a significant impact on the Company’s consolidated financial statements or related Note 3 – Net Income per Common Share Basic net income per share is computed based on the weighted-average number of common shares outstanding. Diluted net income per shareis computed based on the weighted-average number of common shares outstanding, increased by the number of additional shares that wouldhave been outstanding had potentially dilutive common shares been issued and reduced by the number of shares the Company could haverepurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include stockoptions and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the Note 4 – Goodwill and Other Intangible Assets There were no changes in the carrying amount of goodwill during the three months ended March31, 2026. Intangible assets other than goodwill at March31, 2026 and December31, 2025 were as follows: Note 5 – Fa